Not applicableApproved For MarketingNCT05937568What this trial is testingExpanded Access for Treatment With ImetelstatWho this might be right forMyelodysplastic Syndromes Geron Corporation
Large-scale testing (Phase 3)Looking for participantsNCT07422480What this trial is testingCompare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsWho this might be right forMyelodysplastic SyndromeAnemia Takeda 300
Large-scale testing (Phase 3)Ended earlyNCT03263091What this trial is testingEfficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion BurdenWho this might be right forPrimary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)Anemia Kyntra Bio 184
Large-scale testing (Phase 3)Active Not RecruitingNCT03682536What this trial is testingCompare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA NaïveWho this might be right forMyelodysplastic Syndromes Celgene 363
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06594965What this trial is testingHS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic SyndromesWho this might be right forMyelodysplastic SyndromesAnemiaMDS+1 more Hansoh BioMedical R&D Company 176
Early research (Phase 1)Ended earlyNCT04810611What this trial is testingPhase Ib Study of Select Drug Combinations in Patients With Lower Risk MDSWho this might be right forMyelodysplastic Syndromes Novartis Pharmaceuticals 33
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07387354What this trial is testingPacritinib With Aza for Upfront Myelodysplastic SyndromeWho this might be right forMyelodysplastic SyndromesMDSMyelodysplastic Syndrome, Unclassifiable+3 more Thomas Jefferson University 25
Testing effectiveness (Phase 2)Study completedNCT04477850What this trial is testingEvaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell TransfusionsWho this might be right forMyelodysplastic Syndromes Celgene 30
Testing effectiveness (Phase 2)Ended earlyNCT05568225What this trial is testingEtavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)Who this might be right forVery Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Forma Therapeutics, Inc. 17
Testing effectiveness (Phase 2)Active Not RecruitingNCT07052006What this trial is testingA Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and AnemiaWho this might be right forMyelodysplastic SyndromeAnemia in Myelodysplastic Syndromes Halia Therapeutics, Inc. 37
Post-approval studies (Phase 4)Active Not RecruitingNCT05891249What this trial is testingEvaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in IndiaWho this might be right forAnemia Bristol-Myers Squibb 85
Not applicableStudy completedNCT05520749What this trial is testingEfficacy and Safety of Luspatercept: a Study by Fondazione Italiana Sindromi MielodisplasticheWho this might be right forMyeloid Dysplasia Fondazione Italiana Sindromi Mielodisplastiche-ETS 215
Large-scale testing (Phase 3)Study completedNCT02008318What this trial is testingGalunisertib in Participants With Myelodysplastic SyndromesWho this might be right forMyelodysplastic Syndromes Eli Lilly and Company 43
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07319845What this trial is testingTAK-226 for Transfusion-Dependent Anemia in Japanese Patients With Lower-Risk Myelodysplastic SyndromesWho this might be right forMyelodysplastic Syndromes Takeda 27
Large-scale testing (Phase 3)Study completedNCT02631070What this trial is testingLuspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic SyndromesWho this might be right forMyelodysplastic Syndromes Celgene 229
Large-scale testing (Phase 3)Active Not RecruitingNCT05949684What this trial is testingELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood TransfusionsWho this might be right forMyelodysplastic Syndromes Bristol-Myers Squibb 360
Testing effectiveness (Phase 2)Looking for participantsNCT04419649What this trial is testingElritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)Who this might be right forMyelodysplastic SyndromesCytopenia Takeda 160
Large-scale testing (Phase 3)Active Not RecruitingNCT06045689What this trial is testingAssess Luspatercept in Lower-risk Myelodysplastic Syndrome ParticipantsWho this might be right forMyelodysplastic Syndromes Bristol-Myers Squibb 106
Testing effectiveness (Phase 2)Ended earlyNCT05178342What this trial is testingTreatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948Who this might be right forMyelodysplastic SyndromesAnemia University of Leipzig 38
Testing effectiveness (Phase 2)Study completedNCT03900715What this trial is testingAn Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell TransfusionWho this might be right forMyelodysplastic Syndromes Celgene 21